Table 4 Treatment-Related Adverse Events with anlotinib treatment in EGFR mutated NSCLC patients
Type | Anlotinib monotherapy (n = 18) | Anlotinib with ICIs (n = 13) | ||
|---|---|---|---|---|
1–2级 | 3–4级 | 1–2级 | 3–4级 | |
Hand-foot syndrome | 7(38.9%) | 1(5.6%) | 4(30.8%) | 1(7.7%) |
Hypertension | 7(38.9%) | 1(5.6%) | 5(38.5%) | 1(7.7%) |
Fatigue | 6(33.3%) | 1(5.6%) | 4(30.8%) | 2(15.4%) |
Diarrhea | 6(33.3%) | 1(5.6%) | 4(30.8%) | 1(7.7%) |
Anorexia | 5(27.8%) | 1(5.6%) | 5(38.5%) | 0 |
Abnormal liver function | 4(22.2%) | 0 | 4(30.8%) | 0 |
Proteinuria | 5(27.8%) | 1(5.6%) | 3(23.1%) | 0 |
Mucositis oral | 7(18.4%) | 1(2.6%) | 3(23.1%) | 0 |
Thyroid dysfunction | 3(16.7%) | 0 | 1(7.7%) | 0 |
Arthralgia | 2(11.1%) | 0 | 2(15.4%) | 0 |
Headache | 2(11.1%) | 0 | 1(7.7%) | 0 |